+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09717(GCNT3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The GCNT3 (Glucosaminyl (N-Acetyl) Transferase 3) antibody targets an enzyme within the glycosyltransferase family, which plays a critical role in synthesizing mucin-type O-glycans. GCNT3. also known as Core 3 synthase, catalyzes the formation of core 3 O-glycan structures (GlcNAcβ1-3GalNAcα1-Ser/Thr), essential for mucosal protection and cell signaling. Dysregulation of GCNT3 is implicated in cancer progression, particularly in gastrointestinal and pancreatic cancers, where its downregulation correlates with tumor aggressiveness and poor prognosis.

GCNT3 antibodies are primarily used in research to study O-glycosylation patterns, cellular localization, and expression levels in normal vs. diseased tissues. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Recent studies highlight GCNT3's potential as a biomarker for cancers, such as colorectal carcinoma, where its loss may promote metastasis by altering cell adhesion and immune evasion.

Therapeutic interest in GCNT3 is emerging, with antibodies aiding in exploring its role in modulating glycan-mediated pathways or restoring dysregulated glycosylation in malignancies. However, functional complexity and tissue-specific expression of GCNT3 necessitate further validation of antibody specificity and clinical relevance. Overall, GCNT3 antibodies serve as vital tools for unraveling glycosylation mechanisms in disease and guiding biomarker or therapeutic development.